1. Home
  2. LUNR vs IMNM Comparison

LUNR vs IMNM Comparison

Compare LUNR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intuitive Machines Inc.

LUNR

Intuitive Machines Inc.

HOLD

Current Price

$14.00

Market Cap

2.4B

Sector

Industrials

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$23.68

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUNR
IMNM
Founded
2013
2006
Country
United States
United States
Employees
525
N/A
Industry
Industrial Machinery/Components
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
LUNR
IMNM
Price
$14.00
$23.68
Analyst Decision
Buy
Strong Buy
Analyst Count
10
10
Target Price
$22.35
$32.80
AVG Volume (30 Days)
5.6M
790.2K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
84.23
51.40
EPS
N/A
N/A
Revenue
$210,059,000.00
$6,941,000.00
Revenue This Year
$343.00
N/A
Revenue Next Year
$16.81
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.78
$9.36
52 Week High
$46.75
$30.06

Technical Indicators

Market Signals
Indicator
LUNR
IMNM
Relative Strength Index (RSI) 40.54 36.10
Support Level $12.70 $19.03
Resistance Level $16.03 $25.07
Average True Range (ATR) 0.77 1.01
MACD -0.09 -0.52
Stochastic Oscillator 15.31 5.26

Price Performance

Historical Comparison
LUNR
IMNM

About LUNR Intuitive Machines Inc.

Intuitive Machines Inc is a space infrastructure and services company focused on enabling sustained human activity beyond Earth. It designs, builds, integrates, and operates space systems, offering infrastructure-as-a-service across low Earth orbit, geostationary orbit, cislunar space, and deep space. Its capabilities include spacecraft development and space-based network connectivity, serving commercial, civil, and national security customers. The company conducts sales both directly and through an extensive customer and partner network spanning North America, South America, Europe, Asia, and Australia, including rideshare delivery providers, lunar surface mobility providers, payload providers, communication satellite providers, and ground segment providers.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: